Celsius Therapeutics
United States
acquired
acquired
Stage
1
Investors
About
Celsius Therapeutics was a United States–based life sciences/biotechnology company in Catalio Capital's portfolio that focused on developing therapeutic candidates and was exited via M&A in 2024.
Explore Celsius Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.